Evolus Inc
F:EVL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Evolus Inc
F:EVL
|
US |
|
Urban Edge Properties
NYSE:UE
|
US |
|
Transurban Group
ASX:TCL
|
AU |
|
F
|
Fletcher Building Ltd
SWB:FLQ
|
NZ |
|
W
|
White Mountains Insurance Group Ltd
F:WNI
|
US |
|
U
|
United Utilities Group PLC
SWB:UUEC
|
UK |
|
F
|
Fraport AG Frankfurt Airport Services Worldwide
XHAM:FRA
|
DE |
|
D
|
DR Horton Inc
DUS:HO2
|
US |
|
S
|
Stepan Co
F:96S
|
US |
|
C
|
China Life Insurance Co Ltd
SWB:CHL
|
CN |
|
Brunello Cucinelli SpA
OTC:BCUCF
|
IT |
|
C
|
Capital One Financial Corp
LSE:0HT4
|
US |
|
Paramount Global
NASDAQ:PARA
|
US |
|
MTN Group Ltd
OTC:MTNOF
|
ZA |
|
Cass Information Systems Inc
NASDAQ:CASS
|
US |
|
H
|
Hasbro Inc
LSE:0J3K
|
US |
|
Companhia Energetica de Minas Gerais CEMIG
NYSE:CIG.C
|
BR |
|
C
|
Caterpillar Inc
SWB:CAT1
|
US |
|
Interface Inc
NASDAQ:TILE
|
US |
|
E
|
Exxaro Resources Ltd
XBER:LCQ
|
ZA |
|
PDS Biotechnology Corp
NASDAQ:PDSB
|
US |
|
T
|
Tower Bersama Infrastructure Tbk PT
SWB:6TB
|
ID |
|
D
|
Discover Financial Services
SWB:DC7
|
US |
|
A
|
Active Biotech AB publ
STO:ACTI
|
SE |
Evolus Inc
Evolus is a medical aesthetics company best known for Jeuveau, an injectable botulinum toxin used in cosmetic treatments to smooth frown lines. It sells mainly to doctors, med spas, and other licensed aesthetic providers who use the product in office-based procedures for patients paying out of pocket. The company makes money by selling its aesthetic products to these practices rather than to hospitals or insurers. Its business is tied to the self-pay beauty market, where customers choose treatments to improve appearance instead of treating disease. That makes demand depend on consumer spending, provider relationships, and how well its products fit into routine aesthetic practices. What makes Evolus different is its focus on the lower face and cosmetic injection market, not broad medical care. It plays the role of a branded supplier in an industry where doctors often build repeat business around familiar injectable products, training, and patient experience. That gives Evolus a straightforward, product-driven model centered on elective treatments.
Evolus is a medical aesthetics company best known for Jeuveau, an injectable botulinum toxin used in cosmetic treatments to smooth frown lines. It sells mainly to doctors, med spas, and other licensed aesthetic providers who use the product in office-based procedures for patients paying out of pocket.
The company makes money by selling its aesthetic products to these practices rather than to hospitals or insurers. Its business is tied to the self-pay beauty market, where customers choose treatments to improve appearance instead of treating disease. That makes demand depend on consumer spending, provider relationships, and how well its products fit into routine aesthetic practices.
What makes Evolus different is its focus on the lower face and cosmetic injection market, not broad medical care. It plays the role of a branded supplier in an industry where doctors often build repeat business around familiar injectable products, training, and patient experience. That gives Evolus a straightforward, product-driven model centered on elective treatments.
Profitability: Evolus delivered its second straight quarter of positive adjusted EBITDA, even though Q1 is usually its weakest seasonal quarter, showing the benefits of last year’s cost actions.
Revenue: First-quarter global net revenue rose 7% to $73.1 million, led by $66.4 million of Jeuveau revenue and $6.7 million from Evolysse.
Outlook: Management reiterated full-year 2026 guidance, including revenue of $327 million to $337 million and a low to mid-single-digit adjusted EBITDA margin.
Tariffs: A new 15% South Korea tariff on Jeuveau starts September 29, 2026, but management said it does not change the 2026 outlook and said it sees a path to offset the impact.
Portfolio growth: The company said Evolysse traction is improving, bundling is gaining uptake, and Sculpt is still expected to win FDA approval in the fourth quarter.
International: Europe remains a growth engine, and the mid-May launch of Estyme is expected to expand the company’s addressable market, though Q2 stocking is not expected to be material.
